Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Research Publication Suggests Metadichol® Could Reverse Age Related Diseases.

Aging is a law of nature and unavoidable. Instead of targeting a multitude of diseases that confront us as we age Metadichol is about correcting the root cause of diseases as exemplified by our patents and publications. Source. Nanorx Inc


News provided by

Nanorx Inc

Mar 20, 2019, 10:00 ET

Share this article

Share toX

Share this article

Share toX

CHAPPAQUA, N.Y., March 20, 2019 /PRNewswire-PRWeb/ -- Many companies are developing anti-aging drugs using telomerase activation, but Nanorx Inc is paving the way for safe clinical testing.

A recent publication in the Journal of Stem Cell Research & Therapy featured Metadichol®, an immune system booster developed by Nanorx Inc. that has shown promising results for the reversal of aging. The paper, entitled "Quest for Immortality Introducing Metadichol®, a Novel Telomerase Activator," was published on March 5, 2019. The article describes the effect of Metadichol ® on telomerase expression profile on umbilical cord cells. It shows the optimistic research being performed on age reversal.

"As a long term user of Metadichol® for over 5 years, I have seen a 24 percent decrease in my biological age based on measurement of the telomeres length," said Dr. P.R. Raghavan, Chairman, and CEO of Nanorx, Inc. "We have also seen positive changes in other long term users. Use of telomerase to reverse aging is promising and exciting, and we believe Metadichol® could pave the way for this new age."

Public research suggests that telomerase, an enzyme that is found in the cell, is the key to the reversal of aging. Cell division is necessary for the making of new cells. Every time cells divide, they must duplicate their DNA, and telomerase adds repetitive caps called telomeres to the strand. With each division, a portion of the telomeres is shortened, which leads to age-related cellular breakdown. Without telomeres, chromosome ends may fuse and corrupt the cell's genetic blueprint, possibly causing malfunction, cancer, or cell death. Many companies are performing research to prevent telomeres shortening or to lengthen telomeres artificially.

Some companies have developed a procedure to deliver telomerase to cells with the insertion of modified viruses that carry the telomerase gene. This is complicated in practice, as gene therapy has adverse effects, and no human trials are known that express the ability to deliver telomerase effectively to human cells. Metadichol and its expression of telomerase delivery in-vivo to the blood overcomes the hurdles facing researchers in the field.

Metadichol® is an extract from food-based sources and is devoid of toxic effects, and it can be directly tested on humans. It is currently available in an easily absorbable emulsion with the name Metadichol and Nano-Ojas. Metadichol strengthens the immune system and restores balance to other vital functions including wound healing, stimulating cell regeneration and promoting healthy energy levels. Metadichol® acts on the vitamin D nuclear receptors of each cell like an active vitamin D and thus regulates up to 700+ genes of vital importance for the cellular life. Metadichol® paves the way for safe clinical testing and research of telomerase biology and provides enormous medical and financial benefits due to its use in fighting human diseases and reducing the rate of aging.

Nanorx Inc, has published many research papers on the effectiveness of Metadichol® in treating age-related diseases including the expression of Klotho, an anti-aging gene, and the inhibition of the BCAT1 gene, which is implicated in the aging process. The paper in the Journal of Stem Cell Research & Therapy showed that using q-RT-PCR techniques telomerase mRNA gene h-Tert expression showed a sixteen-fold increase at one picogram per ml concentration. Western blot studies showed the expression of Telomerase protein is being maintained at a replacement level. Aging is a law of nature and unavoidable. Instead of targeting a multitude of diseases that confront us as we age Metadichol is about correcting the root cause of diseases as exemplified by our patents and publications. Reversing aging is becoming more attainable, and the future is bright with Metadichol®. Ongoing research and work profiling of other long term users will be reported in an upcoming international conference later this year. The article on Metadichol® and how it potentially reverse signs of aging can be found at http://www.researchgate.net,. Or at http://www.academia.edu.

For licensing and marketing opportunities, contact Dr. P.R. Raghavan at raghavan(at)nanorxinc.com.

Nanorx a privately owned company founded in 2008 in New York that has developed a plant-based nano-eulsion of long-chain aliphatic alcohols, which improves the immune system and balances other vital functions. Metadichol® is covered by US patents and has been granted patents in many other countries. Visit https://www.nanoojas.net/ and http://www.gen100.com to view the company's products.

SOURCE Nanorx Inc

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.